Novel specific metallo-b-lactamase inhibitor ANT2681 restores meropenem activity to clinically effective levels against NDM-positive enterobacterales

37Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The global dissemination of metallo-b-lactamase (MBL)-producing carbapenem-resistant Enterobacterales (CRE) is a serious public health concern. Specifically, NDM (New Delhi MBL) has been a major cause of carbapenem therapy failures in recent years, particularly as effective treatments for serine-b-lactamase (SBL)-producing Enterobacterales are now commercially available. Since the NDM gene is carried on promiscuous plasmids encoding multiple additional resistance determinants, a large proportion of NDM-CREs are also resistant to many commonly used antibiotics, resulting in limited and suboptimal treatment options. ANT2681 is a specific, competitive inhibitor of MBLs with potent activity against NDM enzymes, progressing to clinical development in combination with meropenem (MEM). Susceptibility studies have been performed with MEMANT2681 against 1,687 MBL-positive Enterobacterales, including 1,108 NDM-CRE. The addition of ANT2681 at 8mg/ml reduced the MEM MIC50/MIC90 from .32/ >32mg/ml to 0.25/8mg/ml. Moreover, the combination of 8mg/ml of both MEM and ANT2681 inhibited 74.9% of the Verona integron-encoded MBL (VIM)positive and 85.7% of the imipenem hydrolyzing b-lactamase (IMP)-positive Enterobacterales tested. The antibacterial activity of MEM-ANT2681 against NDM-CRE compared very favorably to that of cefiderocol (FDC) and cefepime (FEP)-taniborbactam, which displayed MIC90 values of 8mg/ml and 32mg/ml, respectively, whereas aztreonam-avibactam (ATM-AVI) had a MIC90 of 0.5mg/ml. Particularly striking was the activity of MEM-ANT2681 against NDM-positive Escherichia coli (MIC90 1mg/ml), in contrast to ATM-AVI (MIC90 4mg/ml), FDC (MIC90 .32mg/ml), and FEP-taniborbactam (MIC90 .32mg/ml), which were less effective due to the high incidence of resistant PBP3-insertion mutants. MEMANT2681 offers a potential new therapeutic option to treat serious infections caused by NDM-CRE.

Cite

CITATION STYLE

APA

Zalacain, M., Lozano, C., Llanos, A., Sprynski, N., Valmont, T., de Piano, C., … Everett, M. (2021). Novel specific metallo-b-lactamase inhibitor ANT2681 restores meropenem activity to clinically effective levels against NDM-positive enterobacterales. Antimicrobial Agents and Chemotherapy, 65(6). https://doi.org/10.1128/AAC.00203-21

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free